Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
One diabetes drug showed superior results for A1C reduction and weight loss.
Read More »Weekly Semaglutide vs. Daily Sitagliptin in T2D Patients
Unique Shake Improves Glycemic Control in T2D
A clinical pilot study reveals a new way to improve glycemic control by replacing daily breakfast and afternoon snacks with a diabetes-specific nutritional shake.
Read More »Hybrid Closed-Loop Insulin Delivery for Children
Young children with type 1 diabetes often experience greater insulin variability, leading to more complications and a subpar quality of life.
Read More »Should Screening for Type 2 Diabetes Be More Aggressive?
Earlier diagnosis and treatment prevent complications.
Read More »Empagliflozin Outcome on Obstructive Sleep Apnea, Cardiovascular, and Renal Events
The unique benefits of using empagliflozin need to be considered when determining treatments for type 2 patients.
Read More »Impact of Physical Activity and Metformin on Postprandial Glucose
Lifestyle modifications as first-line treatment have paramount importance on the quality of life.
Read More »Associations between Prediabetes and Vascular Complications
Do patients with prediabetes share the same vascular complication risk seen in patients with T2D?
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Live Longer and Cardiovascular Disease-Free
How many years can semaglutide add to your life?
Read More »